Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Grifols SA       ES0171996012

End-of-day quote. End-of-day quote  - 12/31
21.315 EUR   -50.22%
03/22 GRIFOLS : Global Blood Product Market 2017 - Grifols, Octapharma, BP..
03/21 Spanish stocks gain 0.77 %
03/13 GRIFOLS : edges closer to zero waste
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2017 4 339 M
EBIT 2017 1 107 M
Net income 2017 653 M
Debt 2017 4 348 M
Yield 2017 1,67%
Sales 2018 4 563 M
EBIT 2018 1 200 M
Net income 2018 730 M
Debt 2018 4 007 M
Yield 2018 1,87%
P/E ratio 2017 23,37
P/E ratio 2018 21,07
EV / Sales2017 4,19x
EV / Sales2018 3,91x
Capitalization 13 842 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments: ... 
Sector
Pharmaceuticals
Calendar
05/04Earnings Release
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
03/22 GRIFOLS : Global Blood Product Market 2017 - Grifols, Octapharma, BPL
03/21 Spanish stocks gain 0.77 %
03/13 GRIFOLS : edges closer to zero waste
03/01 HOLOGIC : Grifols' revenues exceed Euros 4,000 million, driven by +6.5% growth o..
01/31 GRIFOLS : closes the acquisition of Hologic's share of NAT donor screening unit ..
01/27 TERUMO : Global Medical Blood Transfusion Industry 2017 Market Solutions & Life-..
01/11 GRIFOLS : acuerda con Hologic la compra de su participación en la unidad de diag..
01/10 GRIFOLS : to Acquire Hologic Blood Donor Screening Unit
2016 GRIFOLS : Hologic sells blood-screening business to Grifols for $1.85 million
2016 Spanish shares gain 1.58% to close at 9,331 points
More news
Sector news : Biopharmaceuticals
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Biopharmaceuticals
News from SeekingAlpha
2016 Midday Gainers / Losers
2015 Tracking John Paulson's Paulson & Company Portfolio - Q3 2015 Update
2015 TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial
2015 Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Chart GRIFOLS SA
Duration : Period :
Grifols SA Technical Analysis Chart | ES0171996012 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 22,1 €
Spread / Average Target -0,10%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Raimon Grifols Roura Joint Chief Executive Officer & Director
Victor Grifols Deu Joint Chief Executive Officer & Director
Víctor Grifols Roura Chairman
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Eva Bastida Tubau VP, Director-Scientific & Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS SA0.00%14 943
BIOGEN INC5.16%59 348
CSL LIMITED21.87%42 869
ALEXION PHARMACEUTICAL..-2.53%26 787
BIOMARIN PHARMACEUTICA..5.47%15 103
GRIFOLS SA14.67%14 943
More Results